This article is part of the supplement: Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting .

Oral presentation

Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation

A Hombach, C Heuser and H Abken

Tumorgenetik, Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Köln, Germany

author email corresponding author email

from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2^nd Annual Meeting
Mainz, Germany. 6–7 May 2004

Cancer Cell International 2004, 4(Suppl 1):S2doi:10.1186/1475-2867-4-S1-S2

Published:	1 July 2004

First paragraph (this article has no abstract)

The immunoreceptor strategy is based on grafting of T cells with recombinant T cell receptor molecules that consist extracellularily of a scFv domain for MHC-independent antigen binding and intracellularily of the CD3 ζ- or FcεRI γ-signalling domain for cellular activation. Upon binding to antigen-positive cells, grafted T cells are activated, secrete IFN-γ, and lyse specifically antigen-positive, but not antigen-negative target cells. During the last years, we generated a panel of immunoreceptors with specficity for "tumor associated antigens" as targets for use in adoptive immunotherapy of malignant diseases: CEA, CA72-4, CA19-9 for gastrointestinal carcinomas, CD30 for Hodgkin's lymphoma and cutaneous T cell lymphoma, HMW-MAA and melanotransferrin for melanoma, and ErbB2 for a variety of carcinomas [1,2]. T cells taken from the peripheral blood of tumor patients and grafted with the appropriate immunoreceptor mediate a highly efficient immune response towards autologous, antigen expressing target cells in vitro [3].